AstraZeneca, Cellectis Sued Over $2.2 Billion Cancer-Drug Deal

AstraZeneca Plc’s multibillion-dollar drug development deal with Cellectis SA infringes patented gene-editing technology used in cancer cell therapy research, Factor Bioscience Inc. said in a federal lawsuit.

Factor alleges in a complaint filed Friday the companies’ research programs and cell therapy platforms, including Cellectis’ Universal CAR-T and .HEAL technologies and AstraZeneca’s related drug-development deal, infringe US Patent Nos. 10,662,410, 10,829,738, and 10,982,229.

The suit in the US District Court for the District of Delaware seeks damages of at least a reasonable royalty for past infringement and either an order blocking further unauthorized use of the technology or ...